NOVEL SYSTEMS TO EVALUATE SLEEP APNEA AND VIGILANCE

评估睡眠呼吸暂停和警觉性的新系统

• 批准号: 6294876
• 负责人: Daniel J Levendowski
• 金额: $ 10万
• 依托单位: ADVANCED BRAIN MONITORING, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-02-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6294876
• 关键词: attention; clinical research; computer program /software; diagnosis design /evaluation; electroencephalography; heart rate; human subject; memory; patient monitoring device; polysomnography; posture; respiratory airflow disorder; sleep apnea; wakefulness

The proposed research demonstrates the feasibility for two innovative evaluation procedures for diagnostic screening and treatment outcome assessment for sleep apnea (SA). The Alertness for diagnostic screening and treatment outcome assessment for sleep apnea (SA). The Alertness Profiler (AP) combines an easy-to-apply electroencephalographic (EEG) monitoring system and PC-based vigilance, attention and memory tests in a 90-minute protocol designed to quantify levels of daytime drowsiness and their effects on performance. The AP will be evaluated with 20 SA patients and 20 health subjects and referenced to a previously collected normative database. The Apnea Risk Evaluation System (ARES) is an integrated system including: a physiological data acquisition device for monitoring SpO2, pulse, snoring and head position, easily self-applied and comfortably worn overnight to screen for SA; software to identify respiratory events and artifacts; a validated questionnaire to assess risk factors commonly associated with SA; and an expert system to classify individuals into five risk levels for SA. During Phase I, the prototype ARES device will be designed and tested on five health subjects. Software development will begin using data from 30 SA patients. The AP and the ARES can be used together or independently to offer accurate, inexpensive and easy to administer tests for the assessment and monitoring of SA. PROPOSED COMMERCIAL APPLICATIONS: An estimated 20 million people in the U.S. suffer from sleep apnea (SA), the majority undiagnosed. The Alertness Profiler and the Apnea Risk Evaluation System (ARES) offer accurate, inexpensive and easily administered procedures for the assessment and monitoring of SA and the measurement of daytime drowsiness. Both products will be marketed to industry, healthcare and epidemiologists. The ARES will also be sold directly to consumers. A searchable database describing SA prevalence, prognosis and outcome will be created with data generated from these products.

拟议的研究证明了用于睡眠呼吸暂停（SA）诊断筛查和治疗结果评估的两种创新评估程序的可行性。睡眠呼吸暂停 (SA) 诊断筛查和治疗结果评估的警觉性。 Alertness Profiler (AP) 将易于应用的脑电图 (EEG) 监测系统和基于 PC 的警觉性、注意力和记忆力测试结合在一个 90 分钟的协议中，旨在量化白天困倦程度及其对表现的影响。 AP 将由 20 名 SA 患者和 20 名健康受试者进行评估，并参考之前收集的规范数据库。呼吸暂停风险评估系统 (ARES) 是一个集成系统，包括： 用于监测 SpO2、脉搏、打鼾和头部位置的生理数据采集设备，可轻松自我应用并舒适地佩戴过夜以筛查 SA；用于识别呼吸事件和伪影的软件；一份经过验证的问卷，用于评估通常与 SA 相关的风险因素；以及一个专家系统，用于将个人分为五个 SA 风险级别。在第一阶段，原型 ARES 设备将在五个健康受试者身上进行设计和测试。软件开发将开始使用 30 名 SA 患者的数据。 AP 和 ARES 可以一起使用，也可以独立使用，为 SA 的评估和监测提供准确、廉价且易于管理的测试。拟议的商业应用：估计美国有 2000 万人患有睡眠呼吸暂停 (SA)，其中大多数未得到诊断。警觉性分析仪和呼吸暂停风险评估系统 (ARES) 提供准确、廉价且易于管理的程序，用于评估和监测 SA 以及测量白天困倦。这两种产品都将销往工业、医疗保健和流行病学家。 ARES 还将直接销售给消费者。将使用这些产品生成的数据创建一个描述 SA 患病率、预后和结果的可搜索数据库。